These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21875491)

  • 1. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
    Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
    Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
    Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
    Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
    Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
    Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
    J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
    Han A; Chen EH; Niedt G; Sherman W; Ratner D
    Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
    Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
    Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
    Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
    Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
    J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
    Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
    J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions.
    Fernandez-Flores A
    Rom J Morphol Embryol; 2007; 48(4):419-21. PubMed ID: 18060194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.